Mizuho lowered the firm’s price target on CVS Health to $86 from $88 and keeps a Buy rating on the shares. The analyst reduced estimates post the Q3 report on higher utilization in Medicare Advantage.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- Pharmageddon Post-Mortem: CVS (NYSE:CVS), Walgreens (NASDAQ:WBA) Unconcerned
- OKTA Stock’s Sell-Off Presents an Opportunity
- CVS Stock (NYSE:CVS): Don’t Get Ruffled by the Market’s Unhealthy Response
- CVS Health (NYSE:CVS) Slides After Slashing FY23 Outlook
- Unusually active option classes on open November 1st
